Revolution Medicines CEO Mark Goldsmith on new Pancreatic cancer drug breakthrough
3 Articles
3 Articles
Revolution Medicines CEO Mark Goldsmith on new Pancreatic cancer drug breakthrough
Revolution Medicines CEO Mark Goldsmith sits down with CNBC's Angelica Peebles at the American Society of Clinical Oncology's annual meeting to discuss its new Pancreatic cancer drug breakthrough, submitting FDA application for the drug, and more.
New Pancreatic Cancer Drug Could Double Survival Time, Trial Suggests
People with pancreatic cancer typically receive a diagnosis in later stages of the disease, making it one of the most difficult cancers to treat. The overall five-year survival rate is just 14 percent, and that number drops even lower if the cancer has spread (metastasized) to other parts of the body.e60dc2a1-f33c-4a05-9b50-8e3e8e597629d5a91607-f970-4e3b-bd1a-6045835ee81be60dc2a1-f33c-4a05-9b50-8e3e8e597629fb3ce26a-f204-4034-b1eb-72402d52fafe A …
A daily pill can double the survival time of patients with pancreatic cancer, according to a clinical trial. Experts are calling the research “groundbreaking” and one of the biggest breakthroughs in decades. A diagnosis of pancreatic cancer is one of the hardest things to come by. There are currently few treatments for pancreatic cancer, and most of them are only marginally curative. The insidious nature of the disease also doesn’t help: more th…
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium